Is Google's AI best? 💬

Hello there! 👋 Welcome back to AI Creator. Get ready for a dose of exciting AI updates and intriguing reads. Just scroll down to dive in!

⏰ Top 5 Headlines

• 🔗Link: TikTok is introducing new tools and technology to allow creators to label AI-generated content, addressing concerns about transparency and potential confusion among viewers regarding the involvement of AI in content creation.

• 🔗Link: Amazon Web Services CEO Adam Selipsky spreads his AI bets.

• 🔗Link: Cerebral Valley, the AI conference that spawned a $1.3 billion deal, is coming back to San Francisco this year.

• 🔗Link: Workers who use AI produced 40% higher quality results than those who didn’t.

• 🔗Link: Morgan Stanley’s AI assistant marks new era for finance sector.

🚀 Company Spotlight

• 🔗Link: HiddenLayer raises $50 million for its AI-defending cybersecurity tools.

• 🔗Link: AI firm Pryon raises $100 million led by billionaire Thomas Tull.

• 🔗Link: Writer nets $100M for its enterprise-focused generative AI platform.

• 🔗Link: Databricks raises $500M, boosting valuation to $43B despite late-stage gloom.

💬 Tool of the Week

🔗Masterworks: While billionaires typically secure rare and valuable investments, Masterworks, a platform, is democratizing art investment, enabling everyday investors to profit from fractionalized blue-chip artworks, with annualized net returns reaching up to 35%, and Tech Creator readers can join without a waitlist via an exclusive link at masterworks.com/cd.

Google connects A.I. chatbot Bard to YouTube, Gmail and more facts

In March, Google introduced its AI chatbot, Bard, as a response to OpenAI's ChatGPT. Initially falling behind in sophistication and conversational abilities, Google upgraded Bard's technology to compete. Now, Google is aiming to outshine ChatGPT by integrating Bard with popular consumer services like Gmail, Docs, and YouTube, making it a formidable contender in the AI chatbot landscape. Despite the improvements, challenges of trustworthiness and data privacy persist, as AI chatbots continue to evolve and shape our digital interactions. 🔗Dig deeper

The fall of Babylon is a warning for AI unicorns

In 2021, Babylon Health entered the public eye with a staggering valuation of over $4 billion, heralding a promising era for AI in healthcare. Fast forward to 2023, and the once-vaunted unicorn has fallen into bankruptcy, leaving a cautionary tale in its wake. Hugh Harvey, a consultant doctor in the UK's National Health Service, had seen the potential of AI in medicine and joined Babylon Health in its early days. However, insiders now reveal that Babylon couldn't live up to the immense hype it generated, highlighting the challenges and pitfalls that AI unicorns may encounter as they strive to revolutionize industries. 🔗Dig deeper

SoftBank leads Mapbox fundraising as it pushes into AI

Japanese conglomerate SoftBank is leading a $280 million funding round in Mapbox, a US-based location-mapping company, as part of its strategic push into artificial intelligence. This investment aligns with SoftBank founder and CEO Masayoshi Son's commitment to an "counteroffensive" in AI and follows discussions with potential investment targets, including OpenAI. Mapbox's software is integrated into the in-car navigation systems of major automakers like Toyota, BMW, and General Motors, making it vital for autonomous vehicle development. The decision to inject fresh capital into Mapbox comes shortly after SoftBank listed UK chip designer Arm in the US, potentially providing a substantial war chest for Son's AI ambitions. 🔗Dig deeper

AI can help to speed up drug discovery — but only if we give it the right data

In the quest for more effective protein-based drugs, the pharmaceutical industry faces a daunting challenge: less than 10% of protein drug candidates make it through clinical trials. These failures incur astronomical costs and delay potentially life-saving treatments. Protein drugs hold great promise due to their ability to target specific molecules involved in diseases. AI-driven drug development can be a game-changer, but it requires vast datasets. To address this, collaborative efforts among pharmaceutical companies are emerging, harnessing federated learning and active learning techniques to share data while protecting competitive interests. This collaborative approach promises to revolutionize drug development, making it faster, more efficient, and cost-effective, ultimately benefiting patients worldwide. 🔗Dig deeper

🤳 Extra reads

• 🔗Link: How to tell if your A.I. is conscious.

• 🔗Link: Ted Cruz says ‘heavy-handed’ AI regulation will hinder US innovation.

• 🔗Link: Microsoft AI researchers accidentally exposed big cache of data.